References

1. Marshall A. Getting the right drug into the right patient. Nat Biotechnol 1997; 15(12):1249-1252.

2. Drews J, Ryser S. The role of innovation in drug development. Nat Biotechnol 1997; 15(13):1318-1319.

3. Drews J. Strategic trends in the drug industry. Drug Discov Today 2003; 8(9):411-420.

4. Owens J. 2006 drug approvals: Finding the niche. Nat Rev Drug Discov 2007; 6(2):99-101.

5. Cutler DM. The demise of the blockbuster? N Engl J Med 2007; 356(13):1292-1293.

6. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs—will they model the next 100? Nat Rev Drug Discov 2003; 2(1):38-51.

7. Reichert JM. Trends in US approvals: New biopharmaceuticals and vaccines. Trends Biotechnol 2006; 24(7):293-298.

8. Brown D. Overview of sources of new drugs. In: Kennewell PD, editor. Global Perspective. Amsterdam: Elsevier, 2007: 321-353.

9. Clardy J, Walsh C. Lessons from natural molecules. Nature 2004; 432(7019): 829-837.

10. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291(5507):1304-1351.

11. Drews J. Drug discovery: A historical perspective. Science 2000; 287(5460):1960-1964.

12. Hopkins AL, Groom CR. The drugable genome. Nat Rev Drug Discov 2002; 1(9):727-730.

13. Overington JP, Al Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006; 5(12):993-996.

14. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol 2006; 24(7):805-815.

15. Chanda SK, Caldwell JS. Fulfilling the promise: Drug discovery in the post-genomic era. Drug Discov Today 2003; 8(4):168-174.

16. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289(5486):1938-1942.

17. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1(7): 493-502.

18. Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002; 9(4):303-307.

19. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62(24): 7149-7153.

20. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 2003; 9(4):1267-1273.

21. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298(5600):1912-1934.

22. Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, et al. Global analysis of protein activities using proteome chips. Science 2001; 293(5537):2101-2105.

23. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 2000; 407(6802):395-401.

24. Gura T. A chemistry set for life. Nature 2000; 407(6802):282-284.

25. Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. J Cell Sci 2003; 116(Pt 24):4867-4869.

26. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, para-logon groups, and fingerprints. Mol Pharmacol 2003; 63(6):1256-1272.

27. Sadee W, Hoeg E, Lucas J, Wang D. Genetic variations in human G protein-coupled receptors: Implications for drug therapy. AAPS PharmSci 2001; 3(3):E22.

28. Small KM, Tanguay DA, Nandabalan K, Zhan P, Stephens JC, Liggett SB. Gene and protein domain-specific patterns of genetic variability within the G-protein coupled receptor superfamily. Am J Pharmacogenom 2003; 3(1):65-71.

29. Small KM, Seman CA, Castator A, Brown KM, Liggett SB. False positive non-synonymous polymorphisms of G-protein coupled receptor genes. FEBS Lett 2002; 516:253-256.

30. Hepler JR. Emerging roles for RGS proteins in cell signalling. TIPS 1999; 20(Sep): 376-382.

31. De Vries L, Zheng B, Fischer T, Elenko E, Farquhar MG. The regulator of G protein signaling family. Ann Rev Pharmacol Toxicol 2000; 40:235-271.

32. Neubig RR, Siderovski DP. Regulators of G-protein signalling as new central nervous system drug targets. Nat Drug Discov 2002; 1(March):187-197.

33. Zaman GJR, Michiels PJA, van Boeckel CAA. Targeting RNA: New opportunities to address drugless targets. Drug Discov Today 2003; 8(7):297-306.

34. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA apta-mers. Gene Ther 2007; 14(4):283-291.

35. Pollack A. RNA trades bit part for starring role in the cell. New York Times 2003; D1-D4.

36. Jackson DA, Symons RH, Berg P. Biochemical method for inserting new genetic information into DNA of simian virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci USA 1972; 69(10):2904-2909.

37. Whelan J. Beyond PEGylation. Drug Discov Today 2005; 10(5):301.

38. Reichert JM, Paquette C. Therapeutic recombinant proteins: Trends in US approvals 1982 to 2002. Curr Opin Mol Ther 2003; 5(2):139-147.

39. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517):495-497.

40. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306(9):517-522.

41. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003; 9( Jan):129-134.

42. Deo YM, Graziano RF, Repp R, van de Winkel JG. Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today 1997; 18(3): 127-135.

43. Glennie MJ, Van de Winkel JGJ. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003; 8(11 June):503-510.

44. Chowdhury PS, Wu H. Tailor-made antibody therapeutics. Methods 2005; 36(1):11-24.

45. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR. Rational design and engineering of therapeutic proteins. Drug Discov Today 2003; 8(5):212-221.

46. O'Mahony D, Bishop MR. Monoclonal antibody therapy. Front Biosci 2006; 11: 1620-1635.

47. Snell NJ. Examining unmet needs in infectious disease. Drug Discov Today 2003; 8(1):22-30.

48. Baden LR, Curfman GD, Morrissey S, Drazen JM. Human papillomavirus vaccine— opportunity and challenge. N Engl J Med 2007; 356(19):1990-1991.

49. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003; 100(13): 7977-7982.

50. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: Knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 2003; 3(5): 563-570.

51. Marton ML, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ, et al. Drug target validation and identification of secondary drug target effects using DNA mi-croarrays. Nat Med 1998; 4(11):1293-1301.

52. Hughes TR, et al. Functional discovery via a compendium of expression profiles. Cell 2000; 102( Ju1 7):109-126.

53. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, Astromoff A, et al. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet 1999; 21(3):278-283.

54. Hariharan IK, Haber DA. Yeast, flies, worms, and fish in the study of human disease. N Engl J Med 2003; 348(24):2457-2463.

55. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005; 4(1):35-44.

56. Langheinrich U. Zebrafish: A new model on the pharmaceutical catwalk. BioEssays 2003; 25(9):904-912.

57. Renier C, Faraco JH, Bourgin P, Motley T, Bonaventure P, Rosa F, et al. Genomic and functional conservation of sedative-hypnotic targets in the zebrafish. Pharma-cogenet Genomics 2007; 17(4):237-253.

58. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103(5): 1635-1640.

59. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429(6990):457-463.

60. Oki Y, Aoki E, Issa JP. Decitabine—bedside to bench. Crit Rev Oncol Hematol 2007; 61(2):140-152.

61. Conley BA, Wright JJ, Kummar S. Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer 2006; 107(4):832-840.

0 0

Post a comment